streaMLine discovery platform

Machine Learning powered target and drug discovery platform

Gubra's streaMLine platform covers the full spectrum from generation of data to target identification and lead compound generation. Our platform enables pioneering identification of new targets and evaluation of existing ones (preDict), as well as rapid discovery of novel peptides against new or established targets (conClude).

streaMLine preDict for target discovery

Our target discovery platform, streaMLine ***preDict***, combines vast amounts of preclinical data to identify novel druggable targets. We apply advanced analytical methods such as RNAseq, scRNAseq, AI assisted histopathology and various biochemical assays on samples from Gubra´s industry golden standard rodent disease models.

Our preDict algorithm identifies and ranks targets based on unique in-house developed algorithms. Evaluation of clinical data is included to ensure human translatability of targets.

streaMLine conClude for drug discovery

Based on Machine Learning, we have invented an unbiased and systematic approach, streaMLine ***conClude***, to peptide drug discovery. The unique approach has already led to several discoveries of novel peptide structures and functions.

The discovery platform enables us to deliver unprecedented rapid and unbiased synthesis and characterization of complex peptides – up to 3000 lipidated (35-55mer) peptides per month.



Several novel targets have already been identified using our ***preDict*** platform and validated in our AAALAC accredited in vivo facility.

The ***conClude*** platform rapidly generates:

- 3000 peptides/month
- Up to 55mers
- +/- lipidation

Peptides are tested on:

- In vitro pharmacology
- Solubility
- Physical stability